Gentag believes that wearable biosensors linked with NFC devices have the power to transform medical and consumer diagnostics. We first patented the concept of an electronic “second skin” over a decade ago.
From the National Labs to Hospitals and Homes
Radar Responsive Tag, a sophisticated geolocation and tracking technology, is capable of precision locating items or individuals over large areas. First developed at the US National Laboratories for the Department of Defense, these tiny wireless chips, combined with sensors, are capable of providing exquisite location services.
This is a text block. Click the edit button to change this text.
Working to reduce costly hospital readmissions
By linking patients, wearable biological sensors that can be read with an encrypted NFC device, and doctors or hospitals, Gentag is working to reduce costly hospital readmissions, simplify patient discharge, and enable easy in-home self-monitoring.
Wearables for Diagnostics: Gentag’s Disposable NFC Biomarker Patent Receives Notice of Allowance from the European Patent OfficeSeptember 9, 2014Read more
WASHINGTON, DC Sept. 9, 2014 – Gentag, Inc. is pleased to announce that it has been granted a new, additional allowance for its patents in Europe. This allowance, granted by the European Patent Office, further enhances the company’s already significant intellectual property holdings of near field communication (NFC) mobile phone sensor technologies and complements its disposable wearable NFC sensor patent portfolio. The new patent covers quantitative diagnostic tests that can be carried out anywhere – no lab, or costly lab work, needed – using NFC-enabled mobile phones. Multiple diagnostic tests are possible using just a single drop of blood or urine. The...
Gentag’s Wearable Diagnostic Skin Patch Patents Receive Notice of Allowance from the European Patent OfficeAugust 5, 2014Read more
WASHINGTON, DC, August 5, 2014 – Gentag, Inc. is pleased to announce that it has been granted additional allowances for its patents in Europe, which will greatly enhance the company’s already significant intellectual property holdings of near field communication (NFC) sensor technologies related to wearable biosensors, body-area-networks (BAN), sensor diagnostics and advanced geolocation. Gentag’s patents address the uses of disposable diagnostic NFC devices, including skin patches and associated readers in cell phones, and will issue in thirty countries including Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Germany, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg,...